The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Long-term follow-up (FU) of patients with durable complete response (DCR) after chemotherapy (CT) and trastuzumab (T) for HER2-altered (HER2+) metastatic breast cancer (MBC).
Giuseppe Gullo
No relevant relationships to disclose
Monica Zuradelli
No relevant relationships to disclose
Francesco Sclafani
No relevant relationships to disclose
Josephine Ballot
No relevant relationships to disclose
Anne Marie Defrein
No relevant relationships to disclose
Armando Santoro
No relevant relationships to disclose
John Crown
Honoraria - Roche